Key result
Propafenone acts primarily by blocking the fast sodium channel, along with beta-blocking and calcium-channel blocking actions, suggesting efficacy against ventricular and supraventricular arrhythmias.
Propafenone is an antiarrhythmic agent with sodium channel, beta-blocking, and calcium-channel blocking properties, making it effective for ventricular and supraventricular arrhythmias.
May guide antiarrhythmic selection in mixed arrhythmias; leaves open comparative efficacy versus newer agents.
Propafenone is a new antiarrhythmic compound that has an unusual spectrum of pharmacological actions. Its dominant action in cardiac muscle is to block the fast sodium channel with slow onset and offset kinetics. Thus it has a marked depressant effect on conduction with a modest effect in prolonging the effective refractory period in fibers that are fast‐channel dependent. In addition, it has beta‐blocking and calcium‐channel blocking actions that are likely to affect its overall spectrum of activity. Propafenone should be effective in suppressing both ventricular as well as supraventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Bramah N. Singh (1987) conducted a review in Arrhythmias. Propafenone was evaluated. Propafenone acts primarily by blocking the fast sodium channel, along with beta-blocking and calcium-channel blocking actions, suggesting efficacy against ventricular and supraventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: